RAPGEF3 and prostate carcinoma: We have reported that 8-CPT-2Me-cAMP treatment of prostate cancer cells causes about a twofold increase in DNA and protein synthesis which is sensitive to LY-294002, rapamycin, or transfection with Epac1 dsRNA [47], [48].